RSV strains and illness burden in Vietnamese adults aged 60 and older

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational, multicenter enrollment of about 1,000 patients aged 60 years and older admitted with acute respiratory infection (ARI) or exacerbation of chronic cardiopulmonary disease at two Tam Anh hospitals in Ho Chi Minh City. Participants will be screened consecutively, provide consent, and have demographic, clinical, and laboratory data collected from interviews and medical records; respiratory samples will be obtained within 24 hours of admission. Laboratory testing including metagenomic sequencing and viral load measurement will identify RSV infections, genotypes, and co-infections with influenza or SARS‑CoV‑2. Analyses are primarily descriptive, with comparisons between RSV and non‑RSV cases and exploratory modelling (logistic regression and Bayesian Model Averaging) to identify predictors of severe RSV outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

To be enrolled in the study, participants must meet all inclusion criteria:

1. Individuals ≥ 60 years old at the time of screening (calculated from the date of birth to the date of screening)
2. ARI or exacerbation of cardiopulmonary diseases diagnosed at the time of admission. ARI or ARI-compatible symptoms were defined as either:

   * New onset or increase from baseline of: nasal congestion, rhinorrhea, sore throat, hoarseness, cough, sputum production, dyspnea, wheezing, hypoxemia, or
   * Admitting diagnosis suggestive of ARI (e.g., pneumonia, upper respiratory infection, bronchitis, influenza, cough, viral respiratory illness, respiratory distress, or respiratory failure), or
   * Admitting diagnosis was the exacerbation of an underlying cardiac or pulmonary disease involving acute respiratory symptoms within the previous 2 weeks (e.g., congestive heart failure \[CHF\], chronic obstructive pulmonary disease \[COPD\], or asthma exacerbation).
3. The participant agrees to voluntarily participate in this study.

Exclusion Criteria:

To be enrolled in the study, participants must have none of the exclusion criteria:

1. Symptom onset \> 6 days prior to screening date
2. Acute symptoms confirmed to be unrelated to infection or as assessed by the investigator
3. Admission to any hospital within the 30 days preceding the screening date
4. Previously enrolled in the study in the last 45 days

Where it's running

• Tam Anh TP. Ho Chi Minh General Hospital
  Ho Chi Minh City, Southern Vietnam, Vietnam Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ziresovir (AK0529) for high-risk adults with RSV infection

  This study tests whether Ziresovir can shorten RSV-related lower respiratory tract illness in high-risk adults compared with placebo.

  Recruiting at 6 sites Phase 2/3 Shanghai Ark Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 8 other locations · NCT07658534

• Recombinant RSV Vaccine (CHO Cell) with Adjuvant in Adults 18+ in China

  This is a two-part study testing a recombinant RSV vaccine in adults to see if it is safe and whether it provokes an immune response, with older adults (60+) included in the second part.

  Recruiting Phase 1/2 Ab&B Bio-tech Co., Ltd.JS · Zigong, Sichuan · NCT07582796

• Deuremidevir hydrobromide treatment for RSV in infants and young children

  This trial tests whether deuremidevir hydrobromide, given by weight three times daily for five days, helps infants and young children (1–36 months) with confirmed RSV recover faster or have milder symptoms than a placebo.

  Recruiting at 2 sites Phase 3 Simcere Pharmaceutical Co., Ltd · Xiamen, Fujian and 3 other locations · NCT07402512

• S-337395 for high-risk adults with symptomatic RSV

  This trial will test whether taking the antiviral S-337395 within 72 hours of symptoms helps nonhospitalized adults with RSV who are at high risk of progressing to severe illness.

  Recruiting at 88 sites Phase 2 Shionogi Inc. · Los Angeles, California and 88 other locations · NCT07214571

• Remdesivir for RSV in immunocompromised adults

  This trial tests whether a short course of intravenous remdesivir can help adults whose immune systems are weakened by cellular or bispecific antibody therapies recover from upper respiratory RSV infection.

  Recruiting at 3 sites Phase 2 Fred Hutchinson Cancer Center · Duarte, California and 2 other locations · NCT06817889

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.